ITPR3 and B-cell chronic lymphocytic leukemia: Although we previously showed that CLL may be targeted using IP3R-derived peptides, we now provide (i) evidence that this strategy is applicable in other cancer cells like DL-BCL, and (ii) mechanistic insights in the underlying signaling pathways revealing a prominent role for IP3R2.